BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16466399)

  • 1. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
    Crowley MR; Frost A; Chen DT; Baffi MO; Nicola T; Serra R
    Differentiation; 2006 Feb; 74(1):40-52. PubMed ID: 16466399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
    Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
    Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
    Gorska AE; Joseph H; Derynck R; Moses HL; Serra R
    Cell Growth Differ; 1998 Mar; 9(3):229-38. PubMed ID: 9543389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
    Go C; Li P; Wang XJ
    Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
    Amendt C; Schirmacher P; Weber H; Blessing M
    Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.
    Böttinger EP; Jakubczak JL; Roberts IS; Mumy M; Hemmati P; Bagnall K; Merlino G; Wakefield LM
    EMBO J; 1997 May; 16(10):2621-33. PubMed ID: 9184209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of Smad2 and Smad3 in the development of chemically induced skin tumors in mice.
    Tannehill-Gregg SH; Kusewitt DF; Rosol TJ; Weinstein M
    Vet Pathol; 2004 May; 41(3):278-82. PubMed ID: 15133179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
    Labbé E; Lock L; Letamendia A; Gorska AE; Gryfe R; Gallinger S; Moses HL; Attisano L
    Cancer Res; 2007 Jan; 67(1):75-84. PubMed ID: 17210685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mice provide genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways.
    Jhappan C; Takayama H; Dickson RB; Merlino G
    Cell Growth Differ; 1994 Apr; 5(4):385-94. PubMed ID: 8043512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
    Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
    Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
    Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL
    Am J Pathol; 2003 Oct; 163(4):1539-49. PubMed ID: 14507660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
    Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
    Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
    Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
    Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
    Witty JP; Lempka T; Coffey RJ; Matrisian LM
    Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant cell cycle progression contributes to the early-stage accelerated carcinogenesis in transgenic epidermis expressing the dominant negative TGFbetaRII.
    Go C; He W; Zhong L; Li P; Huang J; Brinkley BR; Wang XJ
    Oncogene; 2000 Jul; 19(32):3623-31. PubMed ID: 10951568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.
    Blanco-Aparicio C; Pérez-Gallego L; Pequeño B; Leal JF; Renner O; Carnero A
    Carcinogenesis; 2007 Mar; 28(3):584-94. PubMed ID: 17050554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function.
    Lydon JP; Ge G; Kittrell FS; Medina D; O'Malley BW
    Cancer Res; 1999 Sep; 59(17):4276-84. PubMed ID: 10485472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.